Contrast Agents and Radiopharmaceuticals | Market Insights | US | 2024
The US contrast agents and radiopharmaceutical market was severely impacted by the COVID-19 pandemic in 2020, but has already shown significant recovery in 2021 and 2022; however, it continues to be negatively impacted by disrupted supply chains, particularly due to lockdowns in Shanghai. Growth in the US market for contrast agents and radiopharmaceuticals will be driven by the expanded use of imaging agents in CEUS and PET procedures. However, the market will be somewhat limited by the continued concern over gadolinium and radiation exposure in certain modalities. Additionally, the shift toward value-based care will act as a barrier for certain procedures, favoring instead those that offer the highest levels of accuracy and clarity in visualization.
This Medtech 360 Report provides comprehensive data and analysis on the state of the market for contrast agents and radiopharmaceuticals in the US from 2019 through 2032.
